Statement from Pfenex on the Launch of the First U.S. Biosimilar

Pfenex congratulates Sandoz on the launch of the first FDA-approved biosimilar, Zarxio. The launch of this biosimilar, a first-of-its-kind in the United States, is a critical win for patients and the U.S. healthcare system. Today, patients throughout the country have access to a safe, more affordable alternative innovative therapy – access other geographies have enjoyed for nearly a decade.

Now, it is imperative that regulatory agencies work together to create policies that foster the continued growth of the US biosimilars marketplace, ensuring greater access to safe and affordable biosimilars for patients and cost savings for the healthcare system. Specifically, policies that streamline reimbursement and create clear guidelines for naming and interchangeability are critical to developing a positive environment for biosimilars adoption.

Pfenex is committed to working closely with all stakeholders to educate patients, providers, physicians and lawmakers on the safety and importance of these innovative therapies.